We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases the Future of Diagnostic Solutions at EUROMEDLAB 2022

By LabMedica International staff writers
Posted on 11 Apr 2022

Roche Diagnostics (Basel, Switzerland) showcased its next generation diagnostics solutions that deliver fast and accurate results to help clinicians improve patient care and help reduce the healthcare burden at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EUROMEDLAB) in Munich, Germany. More...

These included the cobas 5800 System that expands access to PCR testing with meaningful and timely results to more patients across the globe, and a new handheld glucose management device, the cobas pulse, powered by the cobas infinity edge suite, that equips healthcare professionals with expanded digital capabilities at the point of care. An evaluation of the recently launched AVENIO Tumour Tissue Comprehensive Genomic Profiling (CGP) Kit for oncology research was also presented. The kit helps expand access to genomic profiling globally, supporting researchers in navigating the complex landscape of cancer research. The findings assess genomic results generated across multiple CGP workflows for variants that are known to cause and drive cancer.

Roche also hosted its very own highly interactive booth, where attendees visited and experienced how the company is helping to improve healthcare. Highlights from the booth included an integrated diagnostics lab and data analytics tools that guide the decision-making process toward optimizing lab operations, customer delivery, and overall lab performance in a targeted and efficient manner. There was also a special interactive area at the booth highlighting Roche’s COVID-19 response. Those unable to attend the congress in person were able to view and engage in the virtual booth via an online portal, with Ro_Bot, a virtual character, as host: Roche EUROMEDLAB 2021. Those joining online were able to follow key sessions via livestream, at no cost. During the congress, Roche also facilitated discussions on key topics in diagnostics today, including three educational workshops.

“Roche is committed to developing innovative solutions that equip healthcare professionals with the tools that allow for earlier diagnosis and more personalized treatment, optimizing patient care and leading to better outcomes,” said Ann Costello, Global Head, Roche Diagnostics Solutions. “We are proud to work in partnership with healthcare professionals across many disease areas and disciplines to enable better healthcare decisions.”

“Lab medicine has always played a key role in healthcare, as proven during the Covid-19 pandemic,” added Moritz Hartmann, Global Head of Roche Information Solutions. “We are working with industry leaders worldwide on digital health solutions to facilitate data-driven decision-making in any setting. This includes labs, clinics and homes with the ultimate goal to improve care for each patient and reduce inefficiencies in healthcare delivery.”

Related Links:
Roche Diagnostics 


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Hematology Consumables
Bioblood Devices
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The researchers Manel Pérez Pons y Carlos Rodriguez Muñoz at the IRBLleida laboratory (Photo courtesy of IRBLleida)

New Blood RNA Markers Help Advance Precision Medicine for Respiratory Patients

Risk stratification in hospitalized respiratory disease, particularly among older adults with COVID-19, remains challenging despite rich clinical datasets. Blood-based non-coding RNA biomarkers are promising,... Read more

Microbiology

view channel
Image: The “broth” used to monitor red blood cell depletion in whole blood spiked with one colony-forming-unit of E. coli bacteria, each incubated at different orbital shaking speeds—left to right: 0 RPM, 65 RPM, 120 RPM and 200 RPM—after four hours of incubation. This culturing raises a bacteria-rich, plasma-like layer of bacteria to the top of the vials, while clusters of stuck blood cells known as a Rouleaux formation sink to the bottom. (Image Credit: Pak Kin Wong)

New Diagnostic Workflow Identifies Bloodstream Pathogens and Antibiotic Response in Hours

Sepsis is a life-threatening complication of infection that affects more than 1.5 million patients annually in the United States and contributes to roughly one in three in-hospital deaths.... Read more

Pathology

view channel
Image: Researchers evaluated AI models that quantify tumor-infiltrating lymphocytes (TIL) on routine breast tissue slides, where higher TIL levels reflect stronger antitumor response and improved breast cancer outcomes (Image Credit: Shutterstock)

AI Matches Pathologists in Predicting Breast Cancer Prognosis from Immune Cells

Breast cancer is the most common cancer in Australian women, with more than 20,000 cases each year. Prognosis can be informed by counting tumor-infiltrating lymphocytes (TILs) on routine pathology slides,... Read more

Industry

view channel
Image: RaDaR ST uses a tumor-informed approach that identifies up to 48 patient-specific variants through whole-exome sequencing and tracks those variants in plasma to detect circulating tumor DNA (ctDNA) at very low variant allele fractions (VAFs) (Photo courtesy of Neogenomics)

Tumor-Informed MRD Assay Gains Medicare Coverage for Immunotherapy Monitoring

NeoGenomics’ RaDaR ST molecular residual disease (MRD) assay has received expanded coverage from the Centers for Medicare & Medicaid Services’ Molecular Diagnostic Services Program (MolDX) for monitoring... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.